DBD is expected to report earnings to rise 83.58% to $1.23 per share on August 12
Q2'26
Est.
$1.23
Q1'26
Beat
by $0.05
Q4'25
Beat
by $1.30
Q3'25
Beat
by $0.28
Q2'25
Missed
by $0.01
The last earnings report on April 30 showed earnings per share of 67 cents, beating the estimate of 62 cents. With 297.04K shares outstanding, the current market capitalization sits at 2.88B.
A.I.dvisor indicates that over the last year, DBD has been loosely correlated with GDRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DBD jumps, then GDRX could also see price increases.
Momentum Indicator for DBD turns positive, indicating new upward trend
DBD saw its Momentum Indicator move above the 0 level on June 18, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator turned positive. In of the 49 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
DBD moved above its 50-day moving average on May 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DBD crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in of 202 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 168 cases where DBD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where DBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DBD turned negative on July 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DBD broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.806) is normal, around the industry mean (25.888). P/E Ratio (28.579) is within average values for comparable stocks, (73.594). DBD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.394). Dividend Yield (0.000) settles around the average of (0.051) among similar stocks. P/S Ratio (0.789) is also within normal values, averaging (52.457).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
